← Back to Clinical Trials
Recruiting NCT05129345

NCT05129345 Addressing Barriers to Achieving Cardiometabolic Disorders Prevention and Treatment Goals for PLWH in the SE US

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05129345
Status Recruiting
Phase
Sponsor Duke University
Condition Hypertension
Study Type OBSERVATIONAL
Enrollment 150 participants
Start Date 2022-06-07
Primary Completion 2026-10-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 150 participants in total. It began in 2022-06-07 with a primary completion date of 2026-10-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study has 3 aims. Aim 1: Identify social determinants of cardiometabolic health and determine facilitators and modifiable barriers in achieving treatment goals. Aim 2: Assess PLWH knowledge, skills, and confidence for self-management of cardiometabolic disorders. Aim 3: Tailor a self-management support and education intervention with stakeholder input to address barriers to achieving treatment goals for cardiometabolic disorders in PLWH at the study sites.

Eligibility Criteria

Inclusion Criteria: Aims 1 and 2 * People living with HIV who are at least 35 years of age and who have one or more of the following conditions: hypertension, dyslipidemia, or type 2 diabetes. Aim 3 * Participants recruited from the participating clinics and community based organizations and may include, HIV providers, nurses, pharmacists, people living with HIV who have cardiometabolic disorders, and representatives of the community advisory boards, and any other key stakeholders. Age 18 or older. Exclusion Criteria: * Those who don't understand English and those who are blind.

Contact & Investigator

Central Contact

Stuart T Carr, BA

✉ stuart.carr@duke.edu

📞 919 668-4849

Principal Investigator

Charles Muiruri, PhD

PRINCIPAL INVESTIGATOR

Duke University

Frequently Asked Questions

Who can join the NCT05129345 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Hypertension. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05129345 currently recruiting?

Yes, NCT05129345 is actively recruiting participants. Contact the research team at stuart.carr@duke.edu for enrollment information.

Where is the NCT05129345 trial being conducted?

This trial is being conducted at Charlotte, United States, Durham, United States.

Who is sponsoring the NCT05129345 clinical trial?

NCT05129345 is sponsored by Duke University. The principal investigator is Charles Muiruri, PhD at Duke University. The trial plans to enroll 150 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology